Chong Kun Dang Pharmaceutical (185750) - Total Assets
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) holds total assets worth ₩1.52 Trillion KRW (≈ $1.03 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Chong Kun Dang Pharmaceutical shareholders equity for net asset value and shareholders' equity analysis.
Chong Kun Dang Pharmaceutical - Total Assets Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical's total assets have evolved over time, based on quarterly financial data.
Chong Kun Dang Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Chong Kun Dang Pharmaceutical's total assets of ₩1.52 Trillion consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 15.7% |
| Accounts Receivable | ₩266.74 Billion | 18.3% |
| Inventory | ₩353.84 Billion | 24.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩75.64 Billion | 5.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 185750 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chong Kun Dang Pharmaceutical's current assets represent 66.0% of total assets in 2024, an increase from 52.8% in 2016.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, up from 3.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 24.3% of total assets.
Chong Kun Dang Pharmaceutical Competitors by Total Assets
Key competitors of Chong Kun Dang Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Chong Kun Dang Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 2.54 | 1.87 |
| Quick Ratio | 1.02 | 1.66 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩409.91 Billion | ₩596.71 Billion | ₩279.49 Billion |
Chong Kun Dang Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Chong Kun Dang Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | ₩1.46 Trillion |
| Market Capitalization | $765.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chong Kun Dang Pharmaceutical's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chong Kun Dang Pharmaceutical's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chong Kun Dang Pharmaceutical (2016–2024)
The table below shows the annual total assets of Chong Kun Dang Pharmaceutical from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.46 Trillion ≈ $988.58 Million |
+4.02% |
| 2023-12-31 | ₩1.40 Trillion ≈ $950.41 Million |
+24.67% |
| 2022-12-31 | ₩1.12 Trillion ≈ $762.32 Million |
+7.47% |
| 2021-12-31 | ₩1.05 Trillion ≈ $709.33 Million |
+10.61% |
| 2020-12-31 | ₩946.33 Billion ≈ $641.32 Million |
+18.09% |
| 2019-12-31 | ₩801.35 Billion ≈ $543.06 Million |
+12.63% |
| 2018-12-31 | ₩711.49 Billion ≈ $482.17 Million |
+5.06% |
| 2017-12-31 | ₩677.21 Billion ≈ $458.93 Million |
+5.53% |
| 2016-12-31 | ₩641.70 Billion ≈ $434.87 Million |
-- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. The company provides prescription drugs for anti-hypertension, anti-hyperlipidemia, anti-diabetics, and immunosuppressants; over-the-counter medicine comprising headache remedies, dewormers, digestive aids, and vitamins; probiotics and Omega-3 supplements; and he… Read more